Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. News
  7. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

WuXi AppTec : STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

08/03/2021 EDT
WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

2021/08/03

State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers

New York & Shanghai, 3rdAugust, 2021:WuXi STA - a subsidiary of WuXi AppTec - today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb(NYSE: BMY). WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA's capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world.

The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, this facility's state-of-the-art tablet & capsule manufacturing and packaging capabilities will provide WuXi STA's customers more flexibility thanks to an enhanced supply of global drug product and greater access to the European market and beyond.

By enhancing its network, WuXi STA can better support customers' long-term needs globally as they bring new and existing commercial manufacturing projects from their pipelines to the facility with the capability and capacity to supply drug products to major global markets.

'We are delighted to have added the Couvet site to our global supply network and are excited to welcome its highly skilled team to the WuXi STA family,' said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. 'Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.'

Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced Middletown site in Delaware of the United States.

-ENDS-

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and control (CMC) from preclinical to commercial uses.

For more information, please visit: http://www.STApharma.com

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,400 collaborators from over 30 countries to improve the health of those in need - and to realize our vision that 'every drug can be made and every disease can be treated.' Please visit: www.wuxiapptec.com

Contacts

Media:

Davy Wu, mediainquiries@wuxiapptec.com

Investors:

Kyler Lei, kyler_lei@wuxiapptec.com

Back

Disclaimer

WuXi AppTec Co. Ltd. published this content on 03 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 20:10:03 UTC.


ę Publicnow 2021
All news about WUXI APPTEC CO., LTD.
10/17WUXI APPTEC : ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services f..
PU
10/06SIRONA BIOCHEM : On Advancement of TFC-1067 Compound
MT
09/22DMD : Charting the Path for New Therapeutics and Better Care
PU
08/25WUXI APPTEC : Investor Day - Financial Performance
PU
08/25WUXI APPTEC : Investor Day - Industry Trend and Company Strategy
PU
08/25WUXI APPTEC : Investor Day - WuXi Biology
PU
08/25WUXI APPTEC : Investor Day - WuXi Chemistry
PU
08/25WUXI APPTEC : Investor Day - WuXi Testing
PU
08/13WUXI APPTEC : H1 Profit Surges 56% on Strong Revenue
MT
08/12WuXi AppTec Co., Ltd. Announces Earnings Results for the Half Year Ended June 30, 2021
CI
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Financials
Sales 2021 22 610 M 3 537 M 3 537 M
Net income 2021 4 383 M 686 M 686 M
Net cash 2021 8 003 M 1 252 M 1 252 M
P/E ratio 2021 88,0x
Yield 2021 0,30%
Capitalization 396 B 61 946 M 61 947 M
EV / Sales 2021 17,2x
EV / Sales 2022 13,0x
Nbr of Employees 28 542
Free-Float 58,3%
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | 603259 | CNE1000031K4 | MarketScreener
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 134,25 CNY
Average target price 185,18 CNY
Spread / Average Target 37,9%
EPS Revisions
Managers and Directors
Min Zhang Chen Co-Chief Executive Officer
Qing Yang Co-CEO, Executive Director & Executive VP
Ge Li Chairman & President
Ellis Chu Chief Financial Officer & Senior Vice President
Harry He Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.19.58%62 553
GILEAD SCIENCES, INC.14.61%83 717
BIONTECH SE241.97%67 329
REGENERON PHARMACEUTICALS22.04%61 299
VERTEX PHARMACEUTICALS-23.44%46 941
BEIGENE, LTD.42.14%34 277